

## Osprey to present at TCT 2016

**October 26, 2016 – Melbourne, Australia and Minnesota, United States** – Osprey Medical (ASX:OSP) is pleased to announce the Company’s scheduled presentations for the upcoming Transcatheter Cardiovascular Therapeutics (“TCT”) Conference, which is being held October 29 to November 2 in Washington, DC.

The TCT is a leading international cardiovascular conference and one of the world’s largest gatherings of heart specialists. The meeting hosts around 11,000 attendees with over 6,000 international medical professionals in the fields of interventional cardiology and vascular medicine.

The complete schedule of Osprey’s presentations is as follows:

### Sunday October 30, 2016

- 7:15am  
Room 143C                      Contrast-Induced Acute Kidney Injury: Focus on Hydration and Dye Saving  
**Dye Saving Tips: The DyeVert Plus System**  
Presented by Professor Steffen Desch
- 7:40am  
Room 143C                      Contrast-Induced Acute Kidney Injury: Focus on Hydration and Dye Saving  
**Practical Application: Incorporating a Hydration and Dye Savings Protocol for Patients at High Risk of AKI**  
Presented by Dr. Prakash Balan
- 8:07am  
Room 209                        Interventional Innovation and Best Technological Concepts I  
**A Novel System to Save Contrast During Coronary Angiography: The DyeVert Randomized Controlled Study**  
Presented by Professor Steffen Desch

### Tuesday November 1, 2016

- 12:30pm  
Room 145B                      Focus on Chronic Kidney Disease and Contrast Nephropathy  
**Contrast Reduction Strategies in the Patient with CKD**  
Presented by Dr. Roxana Mehran

Osprey’s President and CEO, Mike McCormick, said: “A significant component of Osprey’s commercialization strategy is to have its technology featured at the podium by key opinion-leading physicians. Podium presentations increase awareness of our technology within the physician community and enhance the understanding and utility of the DyeVert System. Osprey’s selection for the TCT conference is a vote of confidence in our technology and another opportunity for us to accelerate commercialization of the DyeVert System.”

### Contact details:

#### Media

Amanda Loh  
Buchan Consulting  
T: (613) 8866 1210  
[aloh@buchanwe.com.au](mailto:aloh@buchanwe.com.au)

#### Investors

Rebecca Wilson  
Buchan Consulting  
M: (61) 417 382 391  
[rwilson@buchanwe.co.au](mailto:rwilson@buchanwe.co.au)

#### Company

Doug Schoenberg  
VP of Marketing  
T: (952) 955 8230  
[dschoenberg@osprey-med.com](mailto:dschoenberg@osprey-med.com)

## **About Osprey**

Osprey Medical is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker IDI Heart and Diabetes Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. The Company's DyeVert™ System is a next-generation product that reduces contrast while maintaining image quality in a self-adjusting easy-to-use design. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

## **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.